Trials / Unknown
UnknownNCT00613561
Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago · Academic / Other
- Sex
- All
- Age
- 11 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this study is that children with severe primary immunodeficiencies will benefit from early stem cell transplantation utilizing a reduced intensity conditioning regimen. This regimen is associated with a low risk of complications and will lead to correction of the underlying immunological defects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fludarabine, Busulfan, and Anti-Thymocyte Globulin | Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2012-12-01
- Completion
- 2017-12-01
- First posted
- 2008-02-13
- Last updated
- 2009-05-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00613561. Inclusion in this directory is not an endorsement.